Physician profile
Yang Xu
NPI 1154526515
$3,775.32
in general payments reported to CMS, 2019-2025
32 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $290 · 2021: $721 · 2022: $519 · 2023: $500 · 2024: $573 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $509.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $386.89 | 2020-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $376.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $265.28 | 2019-2024 | Veozah |
| Dexcom, INC. | $261.18 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $243.43 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $172.72 | 2019-2022 | |
| Amarin Pharma, INC. | $154.69 | 2019-2021 | |
| Medtronic, INC. | $152.16 | 2021 | |
| Pfizer INC. | $122.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $63.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.72 | 2019-2022 | |
| Esperion Therapeutics, INC. | $53.97 | 2021-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $51.36 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $51.12 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $46.78 | 2022-2024 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.33 | 2022-2024 | Trulance, Xifaxan |
| Viiv Healthcare Company | $29.58 | 2020 | |
| Abbott Laboratories | $24.96 | 2025 | Cardiomems |
| Otsuka America Pharmaceutical, INC. | $22.75 | 2025 | Rexulti |
| Pacira Therapeutics, INC. | $22.46 | 2019 | |
| Hologic Sales and Service, LLC | $19.70 | 2023 | Aptima |
| Merck Sharp & Dohme LLC | $17.21 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Supernus Pharmaceuticals, INC. | $16.67 | 2025 | Qelbree |
| Inogen, INC. | $15.98 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Baylis Medical Company INC | $13.63 | 2021 | |
| Strongbridge US INC. | $13.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.16 | 2019 | |
| Philips North America LLC | $11.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.